L
LB Pharmaceuticals Inc (LBRX)
NGM – Real Time Price. Currency in USD
31.92
+0.92 (2.97%)
At close: Jun 26, 2026, 4:00 PM EDT
32.19
+0.27 (0.85%)
After-hours: Jun 26, 2026, 7:16 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
31.92
+0.92 (2.97%)
At close: Jun 26, 2026, 4:00 PM EDT
32.19
+0.27 (0.85%)
After-hours: Jun 26, 2026, 7:16 PM EDT
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
| Name | Position |
|---|---|
| Dr. James Rawls Pharm.D. | Senior Vice President of Regulatory Affairs |
| Dr. Richard A. Silva Ph.D. | Senior Vice President of Technical Operations |
| Mr. Gad Soffer | Chief Operating & Business Officer |
| Mr. Marc L. Panoff CPA | Senior Vice President of Finance |
| Ms. Ellen Rose | Senior Vice President of Corporate Affairs |
| Ms. Heather D. Turner Esq., J.D. | CEO & Director |
| Ms. Kaya Pai Panandiker Kamlesh | Chief Commercial Officer |
| Ms. Lindsay Beaupre | Senior VP of People & Culture |
| Ms. Minako Pazdera J.D., Ph.D. | General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-06-10 | 8-K | d221514d8k.htm |
| 2026-06-09 | 8-K | d138757d8k.htm |
| 2026-05-12 | 8-K | d134118d8k.htm |
| 2026-04-23 | DEFA14A | d269343ddefa14a.htm |
| 2026-04-23 | ARS | d269750dars.pdf |
| 2026-04-10 | CORRESP | filename1.htm |
| 2026-04-06 | S-1 | d115802ds1.htm |
| 2026-03-26 | S-8 | d139369ds8.htm |
| 2026-03-26 | 8-K | d129775d8k.htm |
| 2026-03-16 | 8-K | d105454d8k.htm |